ACOR

Acorda Therapeutics, Inc.
ACOR
Market cap $821K

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

About: Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis. The company's Net product revenue is derived from the sales of Ampyra and Inbrija.

Employees: 102

Healthcare Drug Manufacturers - General

Financial journalist opinion

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics announces today the successful acquisition of INBRIJA® (levodopa inhalation powder) and (F)AMPYRA® (fampridine), and related assets from Acorda Therapeutics, Inc. AMPYRA® (dalfampridine) is Food and Drug Administration (FDA) approved in the U.S. and commercialized as FAMPYRA in the European Union and other territories throughout the world. This transaction was conducted through a court-structured 363 sale under the U.S. Bankruptcy Code. The.

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Acorda Therapeutics Announces Delisting from Nasdaq

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Delisting from Nasdaq.

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics Announces Nasdaq Delisting Notification

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.

Acorda Therapeutics Announces Nasdaq Delisting Notification

Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?

Acorda Therapeutics (NASDAQ: ACOR ) stock is falling hard on Tuesday after the biopharmaceutical company signed a stalking horse asset purchase agreement with Merz Therapeutics. This agreement will have Merz Therapeutics acquire substantially all of the company's assets for $185 million.

Acorda Therapeutics shares sink nearly 40% after bankruptcy filing

Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.

Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024.

Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024.

Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.

Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025

See News Rankings

Charts implemented using Lightweight Charts™